Top

Published in:

01-06-2017 | Review Article

Plasminogen activator inhibitor links obesity and thrombotic cerebrovascular diseases: The roles of PAI-1 and obesity on stroke

Authors: Rui Chen, Jinchuan Yan, Peijing Liu, Zhongqun Wang, Cuiping Wang

Published in: Metabolic Brain Disease | Issue 3/2017

Abstract

One of the global socioeconomic phenomena occurred during the last decades is the increased prevalence of obesity, with direct consequence on the risk of developing thrombotic disorders. As the physiological inhibitor of tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1) is well known for its role in fibrinolysis. More and more evidences have shown that PAI-1 involves in physiopathologic mechanisms of many diseases and metabolic disorder. Increased serum level of PAI-1 has been observed in obesity and it also contributes to the development of adipose tissue and then has effects on obesity. Meantime, obesity affects also the PAI-1 levels. These evidences indicate the complicated interaction between PAI-1 and obesity. Many clinic studies have confirmed that obesity relates to the stroke outcome although there are many contradictory results. Simultaneously, correlation is found between plasma PAI-1 and thrombotic cerebrovascular diseases. This article reviews contemporary knowledge regarding the complex interplay of obesity, PAI-1 and stroke.

Ahn CW, Kim CS, Nam JH, Kim HJ, Nam JS, Park JS, Kang ES, Cha BS, Lim SK, Kim KR, Lee HC, Huh KB (2006) Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control. Clin Endocrinol 64:444–449

Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I (1997) Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 46:860–867CrossRefPubMed

Barba R, Marco J, Ruiz J, Canora J, Hinojosa J, Plaza S, Zapatero-Gaviria A (2015) The obesity paradox in stroke: impact on mortality and short-term readmission. J Stroke Cerebrovasc Dis 24:766–770CrossRefPubMed

Bastelica D, Morange P, Berthet B, Borghi H, Lacroix O, Grino M, Juhan-Vague I, Alessi MC (2002) Stromal cells are the main plasminogen activator inhibitor-1 producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol 22:173–178CrossRefPubMed

Cesari M, Pahor M, Incalzi RA (2010) Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther 28:e72–e91CrossRefPubMedPubMedCentral

Cigolini M, Targher G, Bergamo Andreis IA, Tonoli M, Agostino G, De Sandre G (1996) Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 16:368–374CrossRefPubMed

Crandall DL, Quinet EM, Ayachi ES, Hreha AL, Leik CE, Savio DA, Juhan-Vague I, Alessi MC (2006) Modulation of adipose tissue development by pharmacological inhibition of PAI-1. Arterioscler Thromb Vasc Biol 26:2209–2215CrossRefPubMed

De Taeye BM, Novitskaya T, Gleaves L, Covington JW, Vaughan DE (2006) Bone marrow plasminogen activator inhibitor-1 influences the development of obesity. J Biol Chem 281:32796–32805CrossRefPubMed

Declerck PJ, Gils A (2013) Three decades of research on plasminoge n activator inhibitor-1: a multifaceted serpin. Semin Thromb Hemost 39:356–364CrossRefPubMed

Dehlendorff C, Andersen KK, Olsen TS (2014) Body mass index and death by stroke: no obesity paradox. JAMA Neurol 71:978–984CrossRefPubMed

Dichtl W, Ares MP, Stollenwerk M, Giachelli CM, Scatena M, Hamsten A, Eriksson P, Nilsson J (2000) In vivo stimulation of vascular plasminogen activator inhibitor-1 production by very low-density lipoprotein involves transcription factor binding to a VLDL-responsive element. Thromb Haemost 84:706–711PubMed

Eriksson P, Van Harmelen V, Hoffstedt J, Lundquist P, Vidal H, Stemme V, Hamsten A, Arner P, Reynisdottir S (2000) Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals. Thromb Haemost 83:545–548PubMed

Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M, Rubiera M, Mendioroz M, Molina CA, Rosell A, Montaner J (2007) Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients. J Thromb Haemost 5:1862–1868CrossRefPubMed

Giacchetti G, Faloia E, Mariniello B, Sardu C, Gatti C, Camilloni MA, Guerrieri M, Mantero F (2002) Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens 15:381–388CrossRefPubMed

Halleux CM, Deckerck PJ, Tran SL, Detry R, Brichard SM (1999) Hormonal control of plasminogen activator inhibitor-1 gene expression and production in adipose tissue: stimulation by glucocorticoids and inhibition by cathecholamines. J Clin Endocrinol Metab 84:4097–4105PubMed

He G, Pedersen SB, Bruun JM, Lihn AS, Jensen PF, Richelsen B (2003) Differences in plasminogen activator inhibitor 1 in subcutaneous versus omental adipose tissue in non-obese and obese subjects. Horm Metab Res 35:178–182CrossRefPubMed

Jankun J, Skrzypczak-Jankun E (2009) Yin and yang of the plasminogen activator inhibitor. Pol Arch Med Wewn 119:410–417PubMed

Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G (2000) Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/ plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 31:26–32CrossRefPubMed

Kastorini CM, Panagiotakos DB (2012) The obesity paradox: methodological considerations based on epidemiological and clinical evidence--new insights. Maturitas 72:220–224CrossRefPubMed

Keric N, Maier GS, Samadani U, Kallenberg K, Dechent P, Brueck W, Heuer J, Rohde V (2012) Tissue plasminogen activator induced delayed edema in experimental porcine intracranial hemorrhage: reduction with plasminogen activator inhibitor-1 administration. Transl Stroke Res 3:88–93CrossRefPubMedPubMedCentral

Kernan WN, Inzucchi SE, Sawan C, Macko RF, Furie KL (2013) Obesity: a stubbornly obvious target for stroke prevention. Stroke 44:278–286CrossRefPubMed

Kim JW, Lee SH, Ko HM, Kwon KJ, Cho KS, Choi CS, Park JH, Kim HY, Lee J, Han SH, Ignarro LJ, Cheong JH, Kim WK, Shin CY (2011) Biphasic regulation of tissue plasminogen activator activity in ischemic rat brain and in cultured neural cells: essential role of astrocyte-derived plasminogen activator inhibitor-1. Neurochem Int 58:423–433CrossRefPubMed

Kim Y, Kim CK, Jung S, Yoon BW, Lee SH (2015) Obesity-stroke paradox and initial neurological severity. J Neurol Neurosurg Psychiatry 86:743–747CrossRefPubMed

Kindell DG, Keck RW, Jankun J (2015) Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid. Exp Ther Med 9:2339–2343PubMedPubMedCentral

Klaus S (2004) Adipose tissue as a regulator of energy balance. Curr Drug Targets 5:241–250CrossRefPubMed

Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, Okada T, Ohashi K, Hibuse T, Fujita K, Yasui A, Hiuge A, Kumada M, Kuriyama H, Shimomura I, Funahashi T (2006) Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 70:1717–1724CrossRefPubMed

Laumen H, Skurk T, Hauner H (2008) The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes. Atherosclerosis 196:565–573CrossRefPubMed

Le Lay S, Simard G, Martinez MC, Andriantsitohaina R (2014) Oxidative stress and metabolic pathologies: from an adipocentric point of view. Oxidative Med Cell Longev 2014:908539CrossRef

Lijnen HR (2005) Effect of plasminogen activator inhibitor-1 deficiency on nutritionally-induced obesity in mice. Thromb Haemost 93:816–819PubMed

Lijnen HR, Maquoi E, Morange P, Voros G, Van Hoef B, Kopp F, Collen D, Juhan-Vague I, Alessi MC (2003) Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 23:78–84CrossRefPubMed

Lira FS, Rosa JC, Dos Santos RV, Venancio DP, Carnier J, Sanches Pde L, do Nascimento CM, de Piano A, Tock L, Tufik S, de Mello MT, Dâmaso AR, Oyama LM (2011) Visceral fat decreased by long-term interdisciplinary lifestyle therapy correlated positively with interleukin-6 andtumor necrosis factor-α and negatively with adiponectin levels in obese adolescents. Metabolism 60:359–365CrossRefPubMed

Loskutoff DJ, Samad F (1998) The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol 18:1–6CrossRefPubMed

Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, Vaughan DE, Fogo AB (2004) Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53:336–346CrossRefPubMed

Mantovani RM, Rios DR, Moura LC, Oliveira JM, Carvalho FF, Cunha SB, Viana Mde F, Lamounier JA, Castro JC, Dusse LM, Simões e Silva AC (2011) Childhood obesity: evidence of an association between plasminogen activator inhibitor-1 levels and visceraladiposity. J Pediatr Endocrinol Metab 24:361–367CrossRefPubMed

Mavri A, Stegnar M, Krebs M, Sentocnik JT, Geiger M, Binder BR (1999) Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arterioscler Thromb Vasc Biol 19:1582–1587CrossRefPubMed

Morange PE, Aubert J, Pieretti F, Lijnen HR, Vague P, Verdier M, Négrel R, Juhan-Vague I, Alessi MC (1999) Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes 48:890–895CrossRefPubMed

Morange PE, Lijnen HR, Alessi MC, Kopp F, Collen D, Juhan-Vague I (2000) Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol 20:1150–1154CrossRefPubMed

Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, DK MG, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2016) Executive Summary: Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation 133:447–454CrossRefPubMed

Nagai N, Suzuki Y, Van Hoef B, Lijnen HR, Collen D (2005) Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice. J Thromb Haemost 3:1379–1384CrossRefPubMed

Neeland IJ, Ayers CR, Rohatgi AK, Turer AT, Berry JD, Das SR, Vega GL, Khera A, McGuire DK, Grundy SM, de Lemos JA (2013) Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity (Silver Spring) 21:E439–E447

Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ (1986) Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci U S A 83:6776–6780CrossRefPubMedPubMedCentral

Ohkura N, Oishi K, Atsumi G (2015) Blood coagulation and metabolic profiles in middle-aged male and female ob/ob mice. Blood Coagul Fibrinolysis 26:522–526CrossRefPubMed

Oishi K, Koyanagi S, Matsunaga N, Kadota K, Ikeda E, Hayashida S, Kuramoto Y, Shimeno H, Soeda S, Ohdo S (2010) Bezafibrate induces plasminogen activator inhibitor-1 gene expression in a CLOCK-dependent circadian manner. Mol Pharmacol 78:135–141CrossRefPubMed

Olsen TS, Dehlendorff C, Petersen HG, Andersen KK (2008) Body mass index and poststroke mortality. Neuroepidemiology 30:93–100CrossRefPubMed

Orenes-Piñero E, Pineda J, Roldán V, Hernández-Romero D, Marco P, Tello-Montoliu A, Sogorb F, Valdés M, Lip GY, Marín F (2015) Effects of body mass index on the lipid profile and biomarkers of inflammation and a Fibrinolytic and Prothrombotic state. J Atheroscler Thromb 22:610–617CrossRefPubMed

Ovbiagele B, Bath PM, Cotton D, Vinisko R, Diener HC (2011) Obesity and recurrent vascular risk after a recent ischemic stroke. Stroke 42:3397–3402CrossRefPubMed

Pandey M, Tuncman G, Hotamisligil GS, Samad F (2003) Divergent roles for p55 and p75 TNF-alpha receptors in the induction of plasminogen activator inhibitor-1. Am J Pathol 162:933–941CrossRefPubMedPubMedCentral

Placencio VR, DeClerck YA (2015) Plasminogen activator inhibitor-1 in cancer: rationale and insight for future therapeutic testing. Cancer Res 75:2969–2674CrossRefPubMedPubMedCentral

Pou KM, Massaro JM, Hoffmann U, Vasan RS, Maurovich-Horvat P, Larson MG, Keaney JF Jr, Meigs JB, Lipinska I, Kathiresan S, Murabito JM, O'Donnell CJ, Benjamin EJ, Fox CS (2007) Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart study. Circulation 116:1234–1241CrossRefPubMed

Ryu WS, Lee SH, Kim CK, Kim BJ, Yoon BW (2011) Body mass index, initial neurological severity and long-term mortality in ischemic stroke. Cerebrovasc Dis 32:170–176CrossRefPubMed

Samad F, Loskutoff DJ (1996) Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 2:568–582PubMedPubMedCentral

Samad F, Ruf W (2013) Inflammation, obesity, and thrombosis. Blood 122:3415–3422CrossRefPubMedPubMedCentral

Samad F, Uysal KT, Wiesbrock SM, Pandey M, Hotamisligil GS, Loskutoff DJ (1999) Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci U S A 96:6902–6907CrossRefPubMedPubMedCentral

Schäfer K, Fujisawa K, Konstantinides S, Loskutoff DJ (2001) Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 15:1840–1842PubMed

Shin JA, Jeong SI, Kim M, Yoon JC, Kim HS, Park EM (2015) Visceral adipose tissue inflammation is associated with age-related brain changes and ischemic brain damage in aged mice. Brain Behav Immun 50:221–231CrossRefPubMed

Skurk T, Lee YM, Hauner H (2001) Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension 37:1336–1340CrossRefPubMed

Tjärnlund-Wolf A, Brogren H, Lo EH, Wang X (2012) Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases. Stroke 43:2833–2839CrossRefPubMedPubMedCentral

Towfighi A, Ovbiagele B (2009) The impact of body mass index on mortality after stroke. Stroke 40:2704–2708CrossRefPubMed

Uchida Y, Ohba K, Yoshioka T, Irie K, Muraki T, Maru Y (2004) Cellular carbonyl stress enhances the expression of plasminogen activator inhibitor-1 in rat white adipocytes via reactive oxygen species-dependent pathway. J Biol Chem 279:4075–4083CrossRefPubMed

Van De Craen B, Declerck PJ, Gils A (2012) Glycosylation influences the stability of human plasminogen activator inhibitor-1. Blood Coagul Fibrinolysis 23:570–572CrossRefPubMed

Wang Z, Zeng X, Chen Z, Wang X, Zhang L, Zhu M, Yi D (2015) Association of visceral and total body fat with hypertension and prehypertension in a middle-aged Chinese population. J Hypertens 33:1555–1562CrossRefPubMed

Yamamoto K, Takeshita K, Shimokawa T, Yi H, Isobe K, Loskutoff DJ, Saito H (2002) Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals. Proc Natl Acad Sci U S A 99:890–895CrossRefPubMedPubMedCentral

Yamashiro K, Tanaka R, Tanaka Y, Miyamoto N, Shimada Y, Ueno Y, Urabe T, Hattori N (2014) Visceral fat accumulation is associated with cerebral small vessel disease. Eur J Neurol 21:667–673CrossRefPubMed

Yang D, Nemkul N, Shereen A, Jone A, Dunn RS, Lawrence DA, Lindquist D, Kuan CY (2009) Therapeutic administration of plasminogen activator inhibitor-1 prevents hypoxic-ischemic brain injury in newborns. J Neurosci 29:8669–8674CrossRefPubMedPubMedCentral

Zhao R, Ma X, Shen GX (2008) Transcriptional regulation of plasminogen activator inhibitor-1 in vascular endothelial cells induced by oxidized very low density lipoproteins. Mol Cell Biochem 317:197–204CrossRefPubMed

Zhuang P, Wo D, Xu ZG, Wei W, Mao HM (2015) Dynamic changes in plasma tissue plasminogen activator, plasminogen activator inhibitor-1 and beta-thromboglobulin content in ischemic stroke. J Clin Neurosci 22:1123–1127CrossRefPubMed

Title: Plasminogen activator inhibitor links obesity and thrombotic cerebrovascular diseases: The roles of PAI-1 and obesity on stroke
Authors: Rui Chen
Jinchuan Yan
Peijing Liu
Zhongqun Wang
Cuiping Wang
Publication date: 01-06-2017
Publisher: Springer US
Published in: Metabolic Brain Disease / Issue 3/2017
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-017-0007-3

2024 ASCO Annual Meeting

Springer Medicine

Plasminogen activator inhibitor links obesity and thrombotic cerebrovascular diseases: The roles of PAI-1 and obesity on stroke

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

Phytochemical screening, acute toxicity, anxiolytic and antidepressant activities of the Nelumbo nucifera fruit

The oral administration of D-galactose induces abnormalities within the mitochondrial respiratory chain in the brain of rats

Ras-like without CAAX 2 (RIT2): a susceptibility gene for autism spectrum disorder

Fasting leptin and glucose in normal weight, over weight and obese men and women diabetes patients with and without clinical depression

Age-dependent changes of cerebral copper metabolism in Atp7b −/− knockout mouse model of Wilson’s disease by [64Cu]CuCl2-PET/CT

Efficacy and safety of escitalopram in treatment of severe depression in Chinese population